Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

Prior treatment

• Patients receiving any other investigational agents
• Patients who had any surgery of the prostate including TURP (transurethral resection of the prostate)
• Patients who had \> 1 prior prostate biopsy

Other illness

• Patients who have had chemotherapy or radiotherapy within 12 months of the study for other diagnoses not related to prostate cancer
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Patients with active inflammatory bowel disease

Other

• Patients who are unable to undergo MRI

• Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information
  • Note: HIPAA authorization may be included in the informed consent or obtained separately
• Eastern Cooperative Oncology Group (ECOG) performance status of =\< 1 within 3 months (93 days) prior to being registered for protocol
• African-American or white men (Hispanic or non-Hispanic)
• Prostate biopsy-naive or a single negative biopsy
• Having elevated prostate specific antigen (PSA) (\> 2.5 ng/ml) and no palpable nodule on digital rectal exam (DRE)
• Ability to understand the willingness to sign a written informed consent
• Patients must be willing to undergo a radiologic imaging before and after biopsy of the prostate
• Patients must be willing to undergo a biopsy of the prostate